ZLN024 is a novel AMPK allosteric activator and activates α1β1γ1 and α2β1γ1 by around 2-2.5 fold. It activated AMPK in L6 myotubes and stimulated glucose uptake and fatty acid oxidation without increasing the ADP/ATP ratio. It also activated AMPK in primary hepatocytes, decreased fatty acid synthesis and glucose output.